AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Citi Analysts Maintain Buy Rating on Rigel with $67 Price Target
ByAinvest
Thursday, Aug 7, 2025 6:10 am ET1min read
Rigel Pharmaceuticals (RIGL) received a Buy rating and a $67 price target from Citi analyst Yigal Nochomovitz. The analyst has a 4.8% average return and a 40% success rate on recommended stocks. Rigel's latest earnings release showed a quarterly revenue of $53.33 million and a net profit of $11.45 million. The company's shares opened today at $27.18.
Rigel Pharmaceuticals (RIGL) has recently received a positive analyst upgrade from Citi analyst Yigal Nochomovitz, who assigned a Buy rating and a $67 price target to the company's stock. This move follows a series of positive updates from other analysts and strong earnings reports. The company's latest earnings release showed a quarterly revenue of $53.33 million and a net profit of $11.45 million, demonstrating robust financial performance.Analyst Kristen Kluska of Cantor Fitzgerald has also been bullish on Rigel Pharmaceuticals. She maintained a Neutral rating on the stock but significantly raised the price target from $23.00 to $32.00, representing a 39.13% increase [1]. This adjustment follows a previous increase in May 2025, where the price target was raised from $20.00 to $23.00 [1].
The Wall Street consensus is generally positive, with an average target price of $33.74 and a brokerage recommendation of "Outperform" [1]. Rigel's pipeline includes several promising drug candidates, such as TAVALISSE (fostamatinib disodium hexahydrate) tablets, which is the only oral spleen tyrosine kinase (SYK) inhibitor, and R289, a dual IRAK1/4 inhibitor [1].
Rigel Pharmaceuticals is expected to report a 141.4% increase in revenue for the period ending June 30, 2025, with earnings of $2.58 per share, according to analyst estimates [2]. The company's shares opened today at $27.18, indicating a slight increase from the previous close.
The company's strong financial performance and positive analyst sentiment suggest that Rigel Pharmaceuticals is well-positioned to continue its growth trajectory. Investors should closely monitor the company's earnings reports and pipeline developments for further insights into its future prospects.
References:
[1] https://www.gurufocus.com/news/3040807/cantor-fitzgerald-raises-price-target-for-rigl-to-3200-maintains-neutral-rating-rigl-stock-news
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TT396:0-rigel-pharmaceuticals-inc-expected-to-post-earnings-of-2-58-a-share-earnings-preview/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet